Hanmi Pharm's Hypertension Treatment 'Amozaltan Q' Enters Russian Market

Finished Products Manufactured in Paltan, Gyeonggi-do Exported to Russia via Sanofi

[Asia Economy Reporter Kim Ji-hee] Hanmi Pharmaceutical's triple combination drug for hypertension and hyperlipidemia, 'Amozantan Q,' is entering the Russian market through Sanofi.

Hanmi Pharmaceutical announced on the 20th that its partner Sanofi has obtained marketing approval from the Russian Federation Ministry of Health (MOH) for Amozantan Q under the local product name 'Tristanium.' Amozantan Q is a triple combination drug that combines the CCB-class antihypertensive ingredient 'Amlodipine Camylate,' the ARB-class antihypertensive ingredient 'Losartan,' and the hyperlipidemia treatment 'Rosuvastatin.' It is a prescription drug expected to improve medication adherence while effectively treating hypertension and hyperlipidemia.

Hanmi Pharmaceutical grants Sanofi exclusive rights to use the approval data for Amozantan Q in Russia. Sanofi is responsible for local approval, sales, marketing, and distribution in Russia. Following the acquisition of marketing approval, Sanofi plans to establish sales and marketing strategies and proceed with the official launch. Hanmi Pharmaceutical will manufacture the finished products at its Paltan Smart Plant in Gyeonggi Province and export them to Russia.

According to the European Society of Cardiology, Russia, which is the second-largest pharmaceutical market in Europe, has a high prevalence of hypertension, with 4 out of every 10 people affected. However, only about 20% of patients actively receive treatment, indicating significant potential growth for antihypertensive drugs.

The Russian market for the three components of Amozantan Q?amlodipine, losartan, and rosuvastatin?is approximately 400 billion KRW. Last year, Amozantan Q recorded prescription sales in Korea exceeding 10 billion KRW. The two-drug combination Amozantan, which excludes the rosuvastatin component, has been sold in Russia through cooperation with Sanofi since 2017 and has shown an average annual growth rate of 21% over four years.

Woo Jong-su, CEO of Hanmi Pharmaceutical, said, "Amozantan Q is an important product that forms one pillar of the Amozantan family, which records annual prescription sales exceeding 100 billion KRW in Korea," adding, "We will do our best to accelerate global market expansion, starting with Russia."